Alpha Cognition to Participate in Upcoming Investor Events
Business Wire•06/11/2026•15:00 ET
2
Key Highlights
- ➤Alpha Cognition executives to attend Craig-Hallum Alpha Select Conference November 17, 2026
- ➤CEO and COO scheduled for Stonegate CEO Series fireside chat December 10, 2026
- ➤ZUNVEYL approved for Alzheimer’s disease treatment as an acetylcholinesterase inhibitor
- ➤ALPHA-1062 is being developed with memantine and as an intranasal mTBI formulation
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, and Lauren D’Angelo, Chief Operating Officer, will participate in the upcoming investor events:
For further information regarding these events, please reach out to your institutional representative.
Get started
Create a free account to read the full story.